FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. # 01-1635-B	Serial No. # 10/684,957
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Andy Welcher, et al	
		Filing Date: # October 14, 2003	Group: # N/A

OIPE JC185 AUG 1 3 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	4,599,306	07/08/1986	Altrock			
	2.	4,727,138	02/23/1988	Goeddel et al.			
	3.	4,897,264	01/30/1990	Novick et al			
	4.	4,948,738	08/14/1990	Banchereau et al.			
	5.	5,451,658	09/19/1995	Seelig			
	6.	5,852,824	12/10/1996	Goeddel et al.			
	7.	5,632,9888	05/27/1997	Ingram et al.			
	8.	5,693,761	12/02/1997	Queen et al.			
	9.	5,763,210	06/09/1998	Novick et al.			
	10.	5,888,511	03/30/1999	Skurkovich et al.			
	11.	6,333,032	12/25/2001	Skurkovich et al.			
	12.	6,346,247	02/12/2002	Stafford et al.			
	13.	6,350,860	02/26/2002	Buyse et al			
	14.	6,558,661	05/06/2003	Ashkenazi et al.			
	15.	2002/0058033	05/16/2002	Raisch et al.			
	16.	2002/00091240	07/11/2002	Vasquez et al.			
	17.	2003/0056233	03/20/2003	Ehrhardt et al.			
	18.	2003/0059428	03/27/2003	Skurkovich et al.			

EXAMINER	DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	19.	2003/0228310	12/11/2003	Skurkovich et al.			
	20.	2004/0010810	01/15/2004	Kucherlapati et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	21.	DE 4213497 (abst)	10/28/1993					✓
	22.	EP 0528469	07/03/1996					
	23.	WO88/07869	10/20/1988					
	24.	WO91/02005	02/21/1991					
	25.	WO92/06115	04/16/1992					
	26.	WO97/37679	10/16/1997					
	27.	WO99/09055	02/25/1999					
	28.	WO00/71585	11/30/2000					
	29.	WO01/54721	08/02/2001					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	30.	Alkan SS et al., "An Interferon-Gamma Neutralizing Monoclonal Antibody But Not Interferon-Gamma Delays The Induction of Rat Adjuvant Arthritis", Abstract, 1987 ISIR Meeting, Washington, DC, 2-6 Nov 1987, pg. 804, III-17.
	31.	Amital H et al., "Immunomodulation of murine experimental SLE-like disease by interferon-γ ", *Lupus* 1998; 7:445-454.
	32.	Bach J-F, "Immunointervention if Autoimmune Diseases From Cellular Selectivity to Autoantigen Specificity", *J Autoimmune* 1992; 5(Suppl.A):3-10.
	33.	Balasa BB et al., "Interferon γ (IFN- γ) Is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental Autoimmune *Myasthenia gravis* in Mice", *J Exp Med* 1997; 186(3):385-391

EXAMINER	DATE CONSIDERED
	9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	34.	Billiau A, Gamma-interferon: the match that lights the fire?", *Immunol Today* 1988; 9(2):37-40
	35.	Billiau A, "Interferons and Inflammation", *J Interferon Res* 1987; 7:559-567
	36.	Billiau A and Dijkmans R, "Commentary – Interferon- γ " Mechanism of Action and Therapeutic Potential", *Biochem Pharmacol* 1990; 40(7):1433-1439
	37.	Billiau A et al., "Enhancement of Experimental Allergic Encephalomyelitis in Mice By Antibodies Against IFN- γ ", *J Immunol* 1988; 140(5):1506-1510
	38.	Billiau A et al., "A role for the interferon system in the pathogensis of multiple sclerosis?", *J Biol Regul Homeost Agents* 1987; 1:9-22
	39.	Boissier M-C et al., " Immunotherapy of Collagen-Induced Arthritis with Monoclonal Antibody to Interferon- γ)", Abstract, 56th Annual Scientific Meeting, American College of Rheumatology, Oct. 11-15 1992, Atlanta, GA, pg. S99, A186
	40.	Boissier M-C et al., " Biphasic effect of interferon- γ in murine collagen-induced arthritis", *Eur J Immunol* 1995; 25:1184-1190
	41.	Campbell IL et al., "Essential Role for Interferon- γ and Interleukin-6 in Autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice", *J Clin Invest* 1991; 87:739-742
	42.	Chothia C and Lesk AM, "Canonical Structures for the Hypervariable Regions in Immunoglobulins", *J Mol Biol* 1987; 196:901-917
	43.	Cush JJ and Kavanaugh AF, "Biologic Interventions in Rheumatoid Arthritis", *Rheumatoid Arthritis* 1995; 21(3):797-816
	44.	Dijkmans R and Billiau A, "Interferon γ : a master key in the immune system", *Curr Opin Immunol* 1988; 1:269-274
	45.	Duong TT et al., "Effect of anti-interferon- γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse", *J Neuroimmunol* 1992; 36:105-115
	46.	Espejo C et al., "Treatment with Anti-interferon- γ Monoclonal Antibodies Modifies Experimental Autoimmune Encephalomyelitis in Interferon-γ Receptor Knockout Mice", *Exp Neurol* 2001; 172:460-468
	47.	Ferber IA et al., "Mice with a Disrupted IFN- γ Gene Are Susceptible to the Induction of Experimental Autoimmune Encephalomyelitis (EAE)[1]", *J Immunol* 1996; 156:5-7

EXAMINER	DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	48.	Froyen G and Billiau A, "Potential therapeutic use of antibodies directed towards HuIFN-γ", *Biotherapy* 1997; 10:49-57
	49.	Haas C et al., "IFN- γ Receptor Deletion Prevents Autoantibody Production and Glomerulonephritis in Lupus-Prone (NZB x NZW)F_1 Mice[1]", *J Immunol* 1998; 160:3713-3718
	50.	Hartung H-P et al., "The Role of Interferon-Gamma in the Pathogenesis of Experimental Autoimmune Disease of the Peripheral Nervous System", *Ann Neurol* 1990; 27:247-257
	51.	Heremans H and Billiau A, "The Potential Role of Interferons and Interferon Antagonists in Inflammatory Disease", *Drugs* 1989; 38(6):957-972
	52.	Heremans H et al., "Clinical Potential of Monoclonal Antibodies Against Gamma Interferon", *Develop Biol Standard* 1990; 71:113-119
	53.	Heremans H et al., "Interferon γ , A Mediator of Lethal Lipopolysaccharide-Induced Shwartzman-Like Shock Reactions in Mice", *J Exp Med* 1990; 171:1853-1869
	54.	Inagaki Y et al., "Interferon-γ -induced apoptosis and activation of THP-1 macrophages", *Life Sciences* 2002; 71:2499-2508
	55.	Ishida Y et al., "A pivotal involvement of IFN-γ in the pathogenesis of acetaminophen-induced acute liver injury", *FASEB J* 2002; 16:1227-1236
	56.	Jacob CO et al., "In Vivo Treatment of (NZB x $NZWF_1$ Lupus-Like Nephritis with Monoclonal Antibody to γ Interferon", *J Exp Med* 1987; 166:798-803
	57.	Jacob CO et al., "Heterogeneous Effects of IFN-γ In Adjuvant Arthritis[1]", *J Immunol* 1989; 142:1500-1505
	58.	Jones PT et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature* 1986; 321:522-525
	59.	Kageyama Y et al., "Reduced Susceptibility to Collagen-Indiced Arthritis in Mice Deficient in IFN- γ Receptor", *J Immunol* 1998; 161:1542-1548
	60.	Landolfo S et al., "Inhibition of Interferon-Gamma May Suppress Allograft Reactivity by T Lymphocytes in Vitro and in Vivo", *Science* 1985; 229:176-179
	61.	Lukina GV et al., "Double Blind Trial of Effectiveness of Antibodies to Interferon-Gamma and Tumor Necrosis Factor Alpha in Rheumatoid Arthritis", Терапевтический архив 2001; No. 5, C. 12-15

EXAMINER	DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	62.	Lukina GV et al., "New Approaches to Biological Immunomodulation therapy of Rherapy of Rheumatoid Arthritis: Neutralization of Basic Cytokines", Терапевтический архив 1998; No. 5, C. 32-37
	63.	Macdougall IC and Cooper AC, "Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines", *Nephrol Dial Transplant* 2002; 17[Suppl 11]:39-43
	64.	Mizuhara H et al., "Critical Involvement of Interferon Gamma in the Pathogenesis of T-Cell Activation – Associated Hepatitis and Regulatory Mechanisms of Interleukin-6 for the Manifestations of Hepatitis", *Hepatology* 1996; 23:1608-1615
	65.	Nagano H et al., "Coronary Arteriosclerosis after T-Cell-Mediated Injury in Transplanted Mouse Hearts", *Am J Pathol* 1998; 152:1187-1197
	66.	Nakajima H et al., "The effect of treatment with interferon-gamma on type II collagen-induced arthritis", *Clin Exp Immunol* 1990; 81:441-445
	67.	Nicoletti F et al., "Murine Concanavalin A-Induced Hepatitis Is Prevented by Interleukin 12 (IL-12) Antibody and Exacerbated by Exogenous IL-12 Through an Interferon-γ—Dependent Mechanism", *Hepatology* 2000; 32:728-733
	68.	Nicoletti A et al., "Immunoglobulin Treatment Reduces Atherosclerosis in apo E Knockout Mice", *J Clin Invest* 1998; 102:910-918
	69.	Nicoletti F et al., "Prevention of Spontaneous Autoimmune Disbetes in Disbetes-Prone BB Rats by Prophylactic Treatment with Antirat Interferon-γ Antibody", *Endocrinology* 1997; 138:281-288
	70.	Ozmen L et al., "Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-γ *receptor inhibits the onset of* glomerulonephritis*", *Eur J Immunol* 1995; 25:6-12
	71.	Panitch HS et al., "Exacerbations of Multiple Sclerosis in Patients Treated with Gamma Interferon", *Lancet* 1987 Apr 18; 893-895
	72.	Richards HB et al., "Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristine", *Kidney International* 2001; 60:2173-2180
✓	73.	Russell PS et al., "Coronary Atherosclerosis in Transplanted Mouse Hearts[1]", *Transplantation* 1994; 57(9):1367-1371
	74.	Seery JP, IFN-γ transgenic mice: clues to the pathogenesis of systemic lupus erythematosus?", *Arthritis Res* 2000; 2:437-440

EXAMINER	DATE CONSIDERED
	9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	75.	Sigidin YA et al., "Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis", *Scand J Rheumatol* 2001; 30:203-207
	76.	Skurkovich S et al., "Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis", in *Multiple Sclerosis* 2001; 7:277-284
	77.	Skurkovich SV et al., "Successful First-Time Use of Antibodies to Interferon- γ Alone and Combined with Antibodies to Tumor Necrosis Factor-α to Treat Rheumatic Diseases (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis, Behcet's Syndrome)", *Int J Immunotherapy* 1998; XIV(1):23-32
	78.	Skurkovich SV and Eremkina EI, "The Probable Role of Interferon in Allergy", *Annals of Allergy* 1975; 35:356-360
	79.	Skurkovich S et al., "A Unifying Model of the Immunoregulatory Role of the Interferon System: can Interferon Produce Disease in Humans", *Clin Immunol Immunopathol* 1987; 43:362-373
	80.	Skurkovich SV et al., "Lymphocytes' Cytotoxicity Towards Cells of Human Lymphoblastoid Lines in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus", *Annals of Allergy* 1977; 39:344-350
	81.	Skurkovich SV et al., "The Possible Participation of Interferon Inhibitor in the Formation of the Remission in Autoimmune diseases and Allergy (Hypersensitivity of Immediate Type)", *Med Hypoth* 1981; 7:1189-1191
	82.	Skurkovich S et al., "A Disturbance of Interferon Synthesis with the Hyperproduction of Unusual Kinds of Interferon can Trigger Autoimmune Disease and Play a Pathogenetic Role in AIDS: The Removal of These Interferons can be Therapeutic", *Med Hypoth* 1994; 42:27-35
	83.	Tang H et al., "The effexts of a monoclonal antibody to interferon- γ on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells", *Eur J Immunol* 1993; 23:275-278
	84.	Thakur AB and Landolfi NF, "A potent neutralizing monoclonal antibody can discriminate amongst IFN γ from various primates with greater specificity than can the human IFNγ receptor complex", *Mol Immunol* 1999; 36:1107-1115
	85.	Vantrappen G et al., "Treatment of Crohn's Disease with Interferon A Prelimnary Clinical Trial", *Acta Clin Belg* 1980; 35(4):238-242
	86.	Verhoeyen M et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", *Science* 1988; 239:1534-1536

EXAMINER	DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MB/HB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	87.	Whitman SC et al., "IFN-γ Deficiency Exerts Gender-Specific Effects on Atherogenesis in Apolipoprotein $E^{-/-}$ Mice", *J Interferon Cytokine Res* 2002; 22:661-670
	88.	Wiesenberg I et al., "Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody", *Clin Exp Immunol* 1989; 78:245-249
	89.	Williams RO et al., "Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma", *Clin Exp Immunol* 1993; 92:323-327
	90.	Wu AJ et al., "Modulation of MMP-2 (Gelatinase A) and MMP-9 (Gelantinase B) by Interferon-γ in a Human Salivary Gland Cell Line", *J Cell Physiol* 1997; 171:117-124
	91.	Yamamoto Y et al., "Characterization of Mouse Monoclonal Antibodies to Human Interferon-Gamma", *Microbiol Immunol* 1988; 32(4):339-350
	92.	Xu JL and Davis MM, "Difersity in the CDR3 Region of V_H Is Sufficient for Most Antibody Specificities", *Immunity* 2000; 13:37-45
	93.	Zhou X et al., "Hypercholesterolemia Is Associated with a T Helper (Th) 1/Th2 Switch of the Autoimmune Response in Atherosclerotic apo E-knockout Mice", *J Clin Invest* 1998; 101(8):1717-1725
	94.	GenBank Acc: BQ709764, GI:21848663, 7/11/2002
	95.	GenBank Acc: BG758749, GI:14069402, 5/14/2001
	96.	Acc: AL132795; GI:7159766, 8/1/2000
	97.	Acc: AL160175; GI:8217646, 7/5/2002
	98.	Acc: G47578; GI:4494186, 3/23/1999
	99.	Acc: G30544; GI:1594095, 10/5/1996
	100.	EMBL Locus Acc: CAD19912; GI:18041706, 1/1/2002
	101.	EMBL Locus Acc: CAC94629; GI:16116903, 11/15/01
	102.	EMBL Locus Acc: AL591130; GI:13990326, 12/19/2001
	103.	Acc: 1ID2_A; GI:14278664, 4/3/2001
	104.	Acc: AU048895; GI:6722066, 1/20/2000
	105.	Acc: AAU14464, 10/24/2001
	106.	TrEMBL Q9UL89, 5/13/2000

EXAMINER	DATE CONSIDERED
	9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	107.	Acc: A49047; GI:477471, 3/20/1998
	108.	Acc: AAA18271; GI:483388, 5/25/1994
	109.	Acc: AAR66339, 8/4/95
	110.	Acc: BAC01578; GI:21669107, 7/2/2002
	111.	Acc: BAC01595; GI:21669141, 7/2/2002
	112.	Acc: BAC01767; GI:21669485, 7/2/2002
	113.	Acc: AAB99113; GI:1499961, 1/28/1998
	114.	Acc: AAM23996; GI:20515725; 5/9/2002
	115.	Acc: C36006; GI:106413, 12/16/1998
	116.	Acc: AAU02582, 8/29/2001
	117.	Acc: AAG62966, 10/1/2001
	118.	Acc: AAW27555, 1/23/1998
	119.	Acc: AAR66339, 8/4/1995
	120.	Acc: AAR22575, 5/21/1992
	121.	GenBank Acc: BF917294; GI:12308765, 1/18/2001
	122.	GenBank Acc: BQ709764; GI:21848663, 7/11/2002
	123.	GenBank Acc: BG758749; GI:14069402, 5/14/2001
	124.	Acc: AB063950; GI:21669106, 7/2/2002
	125.	GenBank Acc: BG754240; GI:14064893, 5/14/2001
	126.	GenBank Acc: BM920470; GI:19370849, 3/11/2002
	127.	GenBank Acc: BG755575; GI:14066228, 5/14/2001
	128.	GenBank Acc: BF663762; GI:11937657, 12/18/2000
	129.	GenBank Acc: BM008329; GI:16522683, 10/29/2001
	130.	GenBank Acc: BM920470; GI:19370849, 3/11/2002

EXAMINER	DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
Telephone (312) 913-0001

MBHB:
S/N:
Filing Date: